TRAVERE THERAPEUTICS INC (TVTX)
US89422G1076 - Common Stock
| MRQ (2024-3-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 43.25M | 58.18M | 61.70M | 165.80M | 84.80M | |||
| Marketable Securities | 397.79M | 508.68M | 388.60M | 387.10M | 276.80M | |||
| Receivables | 22.73M | 21.18M | 16.60M | 16.20M | 33.10M | |||
| Inventories | 4.53M | 9.41M | 6.90M | 7.30M | 7.60M | |||
| Other Current Assets | 12.77M | 19.34M | 12.60M | 6.50M | 8.10M | |||
| Total Current Assets | 481.08M | 616.77M | 486.40M | 582.80M | 410.40M | |||
| Non-Current Assets | ||||||||
| PPE Net | 24.21M | 25.54M | 30.00M | 34.30M | 35.10M | |||
| Investments And Advances | N/A | N/A | N/A | N/A | N/A | |||
| Goodwill | 753.00K | 753.00K | 900.00K | 900.00K | 900.00K | |||
| Intangibles | 100.43M | 103.69M | 144.10M | 147.50M | 153.20M | |||
| Other Non-Current Assets | 57.08M | 42.16M | 11.10M | 11.10M | 7.80M | |||
| Total Non-Current Assets | 182.47M | 172.14M | 186.20M | 193.80M | 197.00M | |||
| TOTAL ASSETS | 663.55M | 788.91M | 672.60M | 776.60M | 607.40M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | N/A | N/A | N/A | N/A | |||
| Accrued Expenses | 123.75M | 97.89M | 74.10M | 52.20M | 47.00M | |||
| Accounts Payable | 16.73M | 41.67M | 17.30M | 15.10M | 12.10M | |||
| Other Current Liabilities | 32.75M | 38.34M | 50.80M | 56.70M | 33.50M | |||
| Total Current Liabilities | 173.23M | 177.91M | 142.20M | 124.10M | 92.70M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 377.69M | 377.26M | 375.50M | 226.60M | 215.30M | |||
| Deferred Taxes/Income | N/A | N/A | N/A | N/A | N/A | |||
| Other Non-Current Liabilities | 38.55M | 32.93M | 112.00M | 123.90M | 88.20M | |||
| Total Non-Current Liabilities | 416.25M | 410.19M | 487.50M | 350.40M | 303.50M | |||
| TOTAL LIABILITIES | 589.48M | 588.10M | 629.70M | 474.50M | 396.20M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -1.26B | -1.13B | -1.01B | -766.00M | -585.90M | |||
| Additional Paid In Capital | 1.34B | 1.33B | 1.06B | 1.07B | 798.00M | |||
| Common Shares | 8.00K | 7.00K | 0.00 | 0.00 | 0.00 | |||
| Treasury Stock | N/A | N/A | N/A | N/A | N/A | |||
| Other Shareholders' Equity | -1.89M | -1.46M | -2.90M | -600.00K | -900.00K | |||
| Shares Outstanding | 76.11M | 75.37M | 64.30M | 62.50M | 52.20M | |||
| Tangible Book Value per Share | -0.36 | 1.28 | -1.59 | 2.46 | 1.09 | |||
| Total Shareholders' Equity | 74.07M | 200.81M | 42.90M | 302.10M | 211.20M | |||
| TOTAL LIABILITIES AND EQUITY | 663.55M | 788.91M | 672.60M | 776.60M | 607.40M | |||
| Statistics | ||||||||
| Debt/Equity | 5.10 | 1.88 | 8.75 | 0.75 | 1.02 | |||
| Current Ratio | 2.78 | 3.47 | 3.42 | 4.70 | 4.43 | |||
| Return On Assets (ROA) | -24.28% | -14.12% | -41.41% | -23.19% | -27.89% | |||
| Return On Equity (ROE) | -217.53% | -55.47% | -649.18% | -59.62% | -80.21% | |||
All data in USD